Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RenataDHA:RENATA -0.09%85 EV-to-OCF is 14.32 as of Sep. 20, 2026, which is 48% below its 10-year median of 27.47. GuruFocus rates DHA:RENATA with a GF Score™ of 85/100 and a GF Value™ of BDT836.06 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Renata ranks worse than 60.87% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Renata's Enterprise Value is BDT68,679 Mil.
Renata's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was BDT4,795 Mil. Therefore, Renata's EV-to-OCF for today is 14.32.
The historical rank and industry rank for Renata's EV-to-OCF or its related term are showing as below:
DHA:RENATA'
s EV-to-OCF Range Over the Past 10 Years
Min: 9.55 Med: 27.47 Max: 141.5
Current: 14.46
During the past 13 years, the highest EV-to-OCF of Renata was 141.50. The lowest was 9.55. And the median was 27.47.
DHA:RENATA's EV-to-OCF is ranked worse than 60.87% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.12
vs DHA:RENATA: 14.46
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-20), Renata's stock price is BDT453.20.
Renata's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was BDT23.805. Therefore, Renata's PE Ratio (TTM) for today is 19.04.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Renata's share price for today is BDT453.20.
Renata's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT23.805.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Renata EV-to-OCF Related Terms
Renata EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Renata's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Renata's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renata EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Renata's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Renata's EV-to-OCF falls into.
Renata's current Enterprise Value is BDT68,679 Mil.
Renata's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT4,795 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renata (DHA:RENATA) has a EV-to-OCF of 14.32 as of Sep. 20, 2026. This is 48% below median its historical median of 27.47. Over the past decade, Renata's EV-to-OCF has ranged from 9.55 to 141.50. According to the industry distribution chart, Renata ranks #613 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 60.9%.
Is Renata's EV-to-OCF too high?
Renata's current EV-to-OCF of 14.32 is 48% below median its 10-year median of 27.47. Over the past 10 years, this metric has ranged from a low of 9.55 to a high of 141.50. The Drug Manufacturers industry median EV-to-OCF is 10.12. Renata's value of 14.32 is 41.5% above this industry median. Based on the distribution chart, Renata ranks #613 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Renata has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Renata's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Renata ranks #613 out of 1007 companies for EV-to-OCF. This places Renata in the lower half of its industry. The industry median EV-to-OCF is 10.12. Renata's value of 14.32 is 41.5% above this benchmark. Historically, Renata's own EV-to-OCF has ranged from 9.55 to 141.50 over the past decade. While the company's 10-year median is 27.47 vs. the industry median of 10.12, Renata has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.12, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Renata's current EV-to-OCF of 14.32 is 41.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renata's current EV-to-OCF is 14.32, which is 48% below median its own 10-year median of 27.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renata stock overvalued right now?
Based on GuruFocus' analysis, Renata (DHA:RENATA) is currently considered Significantly Undervalued. The stock's GF Value™ is BDT836.06, compared to a current price of BDT453.20 — trading 45.8% below its estimated fair value. The current EV-to-OCF is 14.32, which is 48% below median its 10-year median of 27.47 and 41.5% above the Drug Manufacturers industry median of 10.12. Renata's overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Renata (DHA:RENATA), the current EV-to-OCF is 14.32 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Renata (DHA:RENATA) Overvalued in 2026?
Based on GuruFocus' analysis, Renata stock appears to be undervalued.
The current stock price of BDT453.20 is trading 45.8% below its estimated GF Value™ of BDT836.06.
GuruFocus considers Renata to be Significantly Undervalued.
Key valuation signals for DHA:RENATA:
EV-to-OCF: 14.32 (48% below median its 10-year median of 27.47)
GF Value™: BDT836.06 vs. price of BDT453.20 (45.8% below fair value)
Industry Position: 41.5% above the Drug Manufacturers median (#613 of 1007)
No single metric tells the full story. See the DHA:RENATA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Renata PLC is a Bangladesh based pharmaceutical company. It is engaged in the manufacturing, marketing, and distribution of Human Pharmaceuticals, Animal Health Medicines, Nutritionals, and Vaccines. It manufactures various pharmaceutical products including Beconex Zi Syrup, Cabolin Tablet, Flontin Tablet, Ivana Tablet, and others. Some of the animal health products offered by the company are Doxivet Powder, Fevenil Injection, Diadin Bolus, Renamet Tablet, and others. The company operates in Bangladesh and sells its products locally and internationally.
85GF Score
Get the complete analysis for DHA:RENATA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:RENATA has been successfully added to your 
